ReviewViruses2026
Advances in Nanotechnology for the Treatment of Herpes Virus Infections.
Review in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes simplex virus (HSV) infections present a major global health burden due to their high morbidity. Conventional therapies offer limited efficacy due to poor bioavailability, the need for frequent administration and potential drug resistance. Recent advances in nanotechnology provide opportunities to overcome these limitations. This review summarizes the latest advances in nanocarrier-based formulations, highlighting their role in improving bioavailability, sustained release, mucosal penetration and antiviral activity. An integrative search was conducted from January 2010 to December 2025. Inclusion and exclusion criteria were used to select the articles. After analyzing the articles, 34 were included in this review with in vitro studies and 14 with in vivo assays. These articles were evaluated in relation to physicochemical characterization studies and in vitro and in vivo assays. Studies were found involving polymeric nanoparticles, metal nanoparticles, solid lipid nanoparticles, liposomes, niosomes, nanoemulsions and nanofibers. Regarding in vitro assays, it was observed that the nanosystems showed increased antiviral activity in cell cultures infected with the herpes simplex virus. In addition, developed nanosystems showed prolonged antiviral activity and lowered toxicity in animal models. Thus, these systems prove to be effective when compared to conventional therapy and can be considered an advance in HSV infection therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.